

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.		
				Filing Date 23 Jun 2000	Group 1642	

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
AHT	1	4,968,603	06.11.90	Slamon et al.			
	2	5,183,884	02.02.93	Kraus et al.			
	3	5,480,968	02.01.96	Kraus et al.			
	4	5,641,869	24.06.97	Vandlen et al.			
	5	5,783,186	21.07.98	Arakawa et al.			
	6	5,821,337	13.10.98	Carter et al.			
	7	5,824,311	20.10.98	Greene et al.			
	8	5,882,864	16.03.99	An et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
AHT	9	599,274	01.06.94	EPO				
	10	WO 94/00136	06.01.94	PCT				
	11	WO 94/22478	13.10.94	PCT				
	12	WO 98/16628	23.04.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AHT	13	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)
AHT	14	Agus et al., "Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-dependent and -independent Human Xenograft Models" <u>Cancer Research</u> 59:4761-4764 (1999)
AHT	15	Arteaga et al., "p185 ^{c-erbB-2} Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
AHT	16	Baca et al., "Antibody Humanization Using Monovalent Phage Display" <u>Journal of Biological Chemistry</u> 272(16):10678-10684 (1997)
AHT	17	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
AHT	18	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
AHT	19	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
AHT	20	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
AHT	21	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)
AHT	22	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)
AHT	23	Carraway et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" <u>Nature</u> 387:512-516 (May 1997)

Examiner	<i>Anne L. Zeller</i>	Date Considered	6/14/2005
----------	-----------------------	-----------------	-----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
Aut	24	Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)			
Aut	25	Chang et al., "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" <u>Nature</u> 387:509-512 (May 29, 1997)			
Aut	26	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185 ^{neu}) in normal and transformed epithelial tissues of the digestive tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)			
Aut	27	Craft et al., "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase" <u>Nature Medicine</u> 5(3):280-285 (Mar 1999)			
Aut	28	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)			
Aut	29	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)			
Aut	30	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)			
Aut	31	Earp et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" <u>Breast Cancer Res and Treatment</u> 35:115-132 (1995)			
Aut	32	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)			
Aut	33	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" <u>Molecular & Cellular Biology</u> 6(3):955-958 (Mar 1986)			
Aut	34	Gibson et al., "A novel method for real time quantitative RT-PCR" <u>Genome Research</u> 5(10):995-1001 (Oct 1996)			
Aut	35	Groenen et al., "Structure-Function Relationships for the EGF/TCF- α Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)			
Aut	36	Gu et al., "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia" <u>Cancer Lett.</u> 99:185-189 (1996)			
Aut	37	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res</u> 3:21-31 (1988)			
Aut	38	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)			
Aut	39	Harari et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase" <u>Oncogene</u> 18:2681-2689 (1999)			
Aut	40	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)			
Aut	41	Heid et al., "Real time quantitative PCR" <u>Genome Research</u> 6(10):986-994 (Oct 1996)			
Aut	42	Holmes et al., "Identification of Heregulin, a Specific Activator of p185 ^{erbB2} " <u>Science</u> 256:1205-1210 (May 22, 1992)			
Aut	43	Hudziak et al., "Increased expression of the putative growth factor receptor p185 ^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84(20):7159-7163 (Oct 1987)			
Examiner		Anne L. Holleran		Date Considered 6/14/2005	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
Alit	44	Hudziak et al., "p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)			
Alit	45	Jones et al., "Binding Interaction of the Heregulin egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis" <u>Journal of Biological Chemistry</u> 273(19):11667-11674 (May 8, 1998)			
	46	Kabat Sequences of Proteins of Immunological Interest, US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1981)			
Alit	47	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)			
Alit	48	Kern et al., "p185 ^{neu} Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)			
Alit	49	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)			
Alit	50	Klapper et al., "A subclass of tumor inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" <u>Oncogene</u> 14:2099-2109 (1997)			
Alit	51	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)			
Alit	52	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <u>Proc. Natl. Acad. Sci. USA</u> 86:9193-9197 (Dec 1989)			
Alit	53	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular & Cellular Biology</u> 11(2):979-986 (Feb 1991)			
Alit	54	Lee et al., "Transforming Growth Factor α : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)			
Alit	55	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)			
Alit	56	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)			
Alit	57	Lewis et al., "Differential responses of human tumor cell lines to anti-p185 ^{HER2} monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)			
Alit	58	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)			
Alit	59	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)			
Alit	60	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)			
Alit	61	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)			
Alit	62	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)			
Alit	63	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 ^{erbB2} " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)			
Examiner		<i>Amel Holleran</i>		Date Considered 6/14/2005	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
ALH	64	Myers et al., "Biological Effects of Anti-Human Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185neu" <u>Methods in Enzymology</u> 198:277-290 (1991)			
ALH	65	Nagabhushan et al., "CWR22: The First Human Prostate Cancer Xenograft with Strongly Androgen-dependent and Relapsed Strains Both in Vivo and in Soft Agar" <u>Cancer Research</u> 56:3042-3046 (1996)			
ALH	66	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)			
ALH	67	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <u>Oncogene</u> 9:1829-1838 (1994)			
ALH	68	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4" <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)			
ALH	69	Plowman et al., "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)			
ALH	70	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)			
ALH	71	Ross et al., "HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence in Situ Hybridization" <u>Hum. Pathol.</u> 28(7):827-833 (July 1997)			
ALH	72	Ross et al., "Prognostic Significance of HER-2/neu Gene Amplification Status by Fluorescence In Situ Hybridization of Prostate Carcinoma" <u>Cancer</u> 79(11):2162-2170 (June 1, 1997)			
ALH	73	Sadasivan et al., "Overexpression of Her-2/Neu May Be An Indicator of Poor Prognosis in Prostate Cancer" <u>J. Urol.</u> 150:126-131 (Jul 1993)			
ALH	74	Sarup et al., "Characterization of an Anti-P185HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)			
ALH	75	Schaefer et al., "A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 is required for Transactivation of ErbB2" <u>Journal of Biological Chemistry</u> 274(2):859-866 (Jan 8, 1999)			
ALH	76	Schaefer et al., "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175" <u>Oncogene</u> 15:1385-1394 (1997)			
ALH	77	Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)			
ALH	78	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)			
ALH	79	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)			
ALH	80	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)			
ALH	81	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)			
ALH	82	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)			
ALH	83	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)			
Examiner <i>Amel C. Halloran</i>				Date Considered 6/14/2005	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)					
84	Stearns et al., "Workgroup 2: Human Xenograft Models of Prostate Cancer" <u>Prostate</u> 36:56-58 (1998)				
85	Sugarman et al., "Recombinant Human Tumor Necrosis Factor- α : Effects on Proliferation of Normal and Transformed Cells in Vitro" <u>Science</u> 230:943-945 (1985)				
86	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)				
87	Vitetta et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)				
88	Wainstein et al., "CWR22: Androgen-dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma" <u>Cancer Research</u> 54:6049-6052 (1994)				
89	Weiner et al., "Expression of the neu Gene-encoded Protein (P185 ^{neu}) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Research</u> 50(2):421-425 (Jan 15, 1990)				
90	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996)				
91	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59(1):46-52 (1991)				
92	Wofsy et al., "Modification and Use of Antibodies to Label Cell Surface Antigens" <u>Selected Methods in Cellular Immunology</u> , Mishel and Schiigi, eds., San Francisco:WJ Freeman Co., Chapter 13, pps. 287-304 (1980)				
93	Wu et al., "Apoptosis Induced By an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay By Insulin" <u>Journal of Clinical Investigation</u> 95(4):1897-1905 (Apr 1995)				
94	Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185" <u>International Journal of Cancer</u> 53(3):401-408 (Feb 1, 1993)				
95	Yokota et al., "Amplification of c-erbB-2 Oncogene in Human Adenocarcinomas in Vivo" <u>Lancet</u> 1(8484):765-767 (Apr 5, 1986)				
96	Yonemura et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer" <u>Cancer Research</u> 51(3):1034-1038 (Feb 1, 1991)				
97	Zhang et al., "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4" <u>Proc. Natl. Acad. Sci. USA</u> 94:9562-9567 (Sep 22, 1997)				
98	Zhou et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" <u>Molecular Carcinogenesis</u> 3(5):254-257 (1990)				
Examiner	<i>Amel Hilleran</i>	Date Considered	6/14/2005		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					